Executives at Viridian Therapeutics disclosed during a conference call that the pricing plan for a five-infusion course of its drug Lumvoa, used to treat thyroid eye disease, is roughly equivalent to the total price of an eight-standard-infusion course of Tepezza, a competing drug from Amgen.

老虎证券2026/06/29 12:32

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.